AQST
Price
$5.42
Change
+$0.36 (+7.11%)
Updated
Sep 5 closing price
Capitalization
655.68M
65 days until earnings call
MKGAF
Price
$129.15
Change
+$1.90 (+1.49%)
Updated
Sep 5 closing price
Capitalization
55.52B
Interact to see
Advertisement

AQST vs MKGAF

Header iconAQST vs MKGAF Comparison
Open Charts AQST vs MKGAFBanner chart's image
Aquestive Therapeutics
Price$5.42
Change+$0.36 (+7.11%)
Volume$6.08M
Capitalization655.68M
Merck KGaA
Price$129.15
Change+$1.90 (+1.49%)
Volume$594
Capitalization55.52B
AQST vs MKGAF Comparison Chart in %
Loading...
AQST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MKGAF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AQST vs. MKGAF commentary
Sep 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AQST is a StrongBuy and MKGAF is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 07, 2025
Stock price -- (AQST: $5.42 vs. MKGAF: $129.15)
Brand notoriety: AQST and MKGAF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AQST: 366% vs. MKGAF: 111%
Market capitalization -- AQST: $655.68M vs. MKGAF: $55.52B
AQST [@Pharmaceuticals: Generic] is valued at $655.68M. MKGAF’s [@Pharmaceuticals: Generic] market capitalization is $55.52B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.94B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AQST’s FA Score shows that 0 FA rating(s) are green whileMKGAF’s FA Score has 1 green FA rating(s).

  • AQST’s FA Score: 0 green, 5 red.
  • MKGAF’s FA Score: 1 green, 4 red.
According to our system of comparison, AQST is a better buy in the long-term than MKGAF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AQST’s TA Score shows that 5 TA indicator(s) are bullish while MKGAF’s TA Score has 3 bullish TA indicator(s).

  • AQST’s TA Score: 5 bullish, 5 bearish.
  • MKGAF’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, AQST is a better buy in the short-term than MKGAF.

Price Growth

AQST (@Pharmaceuticals: Generic) experienced а +43.77% price change this week, while MKGAF (@Pharmaceuticals: Generic) price change was +4.36% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.10%. For the same industry, the average monthly price growth was +12.13%, and the average quarterly price growth was +87.01%.

Reported Earning Dates

AQST is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.10% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MKGAF($55.5B) has a higher market cap than AQST($656M). AQST YTD gains are higher at: 52.247 vs. MKGAF (-14.786). MKGAF has higher annual earnings (EBITDA): 5.87B vs. AQST (-47.5M). MKGAF has more cash in the bank: 1.57B vs. AQST (60.5M). AQST has less debt than MKGAF: AQST (40.3M) vs MKGAF (9.4B). MKGAF has higher revenues than AQST: MKGAF (21.2B) vs AQST (44.1M).
AQSTMKGAFAQST / MKGAF
Capitalization656M55.5B1%
EBITDA-47.5M5.87B-1%
Gain YTD52.247-14.786-353%
P/E RatioN/A16.81-
Revenue44.1M21.2B0%
Total Cash60.5M1.57B4%
Total Debt40.3M9.4B0%
FUNDAMENTALS RATINGS
AQST vs MKGAF: Fundamental Ratings
AQST
MKGAF
OUTLOOK RATING
1..100
2864
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
23
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10070
PRICE GROWTH RATING
1..100
3778
P/E GROWTH RATING
1..100
10092
SEASONALITY SCORE
1..100
385

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MKGAF's Valuation (23) in the null industry is in the same range as AQST (36) in the Pharmaceuticals Major industry. This means that MKGAF’s stock grew similarly to AQST’s over the last 12 months.

MKGAF's Profit vs Risk Rating (100) in the null industry is in the same range as AQST (100) in the Pharmaceuticals Major industry. This means that MKGAF’s stock grew similarly to AQST’s over the last 12 months.

MKGAF's SMR Rating (70) in the null industry is in the same range as AQST (100) in the Pharmaceuticals Major industry. This means that MKGAF’s stock grew similarly to AQST’s over the last 12 months.

AQST's Price Growth Rating (37) in the Pharmaceuticals Major industry is somewhat better than the same rating for MKGAF (78) in the null industry. This means that AQST’s stock grew somewhat faster than MKGAF’s over the last 12 months.

MKGAF's P/E Growth Rating (92) in the null industry is in the same range as AQST (100) in the Pharmaceuticals Major industry. This means that MKGAF’s stock grew similarly to AQST’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AQSTMKGAF
RSI
ODDS (%)
Bearish Trend 2 days ago
82%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
74%
Bullish Trend 2 days ago
68%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
67%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
65%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
64%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
62%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 4 days ago
59%
Declines
ODDS (%)
Bearish Trend 9 days ago
89%
Bearish Trend 9 days ago
63%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
74%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
AQST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MKGAF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IUESX29.120.11
+0.38%
JPMorgan International Focus I
JLCWX76.06N/A
N/A
JHancock Fundamental Large Cap Core R6
BUITX24.01N/A
N/A
Buffalo Mid Cap Discovery Inst
GCINX15.37N/A
N/A
Green Century MSCI Intl Indx Indvl Inv
CGLAX18.20-0.05
-0.27%
Calvert Global Equity Fund Class A

AQST and

Correlation & Price change

A.I.dvisor tells us that AQST and ESPR have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AQST and ESPR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AQST
1D Price
Change %
AQST100%
+7.11%
ESPR - AQST
32%
Poorly correlated
+5.93%
NBIX - AQST
31%
Poorly correlated
+2.64%
HROW - AQST
30%
Poorly correlated
+2.18%
SCYX - AQST
30%
Poorly correlated
+2.43%
BCRX - AQST
28%
Poorly correlated
N/A
More

MKGAF and

Correlation & Price change

A.I.dvisor indicates that over the last year, MKGAF has been loosely correlated with MKKGY. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if MKGAF jumps, then MKKGY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MKGAF
1D Price
Change %
MKGAF100%
+1.49%
MKKGY - MKGAF
49%
Loosely correlated
+1.66%
AQST - MKGAF
19%
Poorly correlated
+7.11%
INDV - MKGAF
17%
Poorly correlated
+1.01%
EVO - MKGAF
17%
Poorly correlated
+3.26%
EBS - MKGAF
16%
Poorly correlated
-0.66%
More